Hepatitis B is not an intergenerational disease. As long as the pregnant woman does not carry the hepatitis B virus, the newborn will not be infected with the hepatitis B virus. If a pregnant woman carries the hepatitis B virus, she can pass it on to her newborn during the perinatal period. If she carries the hepatitis B virus, she should undergo mother-to-child interruption of treatment (PMTCT). PMTCT involves administering anti-hepatitis B immunoglobulin and hepatitis B vaccine to the newborn within 12 hours of birth. However, the success rate is currently reported to be 95%, and the other 5% can still be transmitted intrauterinally by the pregnant woman. To ensure that the newborn is not infected with the hepatitis B virus, antiviral drugs can be administered to the pregnant woman. The current regimen of antiviral therapy for pregnant women is oral tenofovir antiviral therapy in late pregnancy, which is not considered teratogenic to the fetus and is safe for pregnant women.